Navigation Links
Angeion Corporation Reports First Quarter Fiscal Year 2012 Operating Results
Date:2/28/2012

ng, we will now move ahead to reconfigure the company for future growth. We believe there are outstanding opportunities in new markets such as primary care, home monitoring and telemedicine that can benefit from MedGraphics technology."

Balance Sheet
As of January 31, 2012, the Company ended the first quarter fiscal 2012 with cash, equivalents and short term investments totaling $9.2 million, working capital of $13.3 million, no long-term debt and shareholders' equity of $14.2 million. For the first quarter, the Company repurchased a total of 1,000 shares of Angeion common stock in the open market for an average price of $4.98 per share. Under the current stock repurchase program, the Company has the authorization to purchase an additional $2.8 million worth of stock and is prepared to take advantage of opportunistic buying situations.

Conference Call
The Company has scheduled a conference call for February 28, 2012 at 5:00 p.m. ET to discuss its financial results for the first quarter fiscal 2012.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at www.angeion.com. A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10010101, through March 5, 2012. A webcast replay of the conference call will be accessible on the Company's website at www.angeion.com for 90 days.

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand names. T
'/>"/>

SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results
3. Angeion Corporation to Report Fourth Quarter and Fiscal Year 2011 Financial Results on Friday, December 16, 2011
4. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
5. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Human Insulin Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778) Explore more about Global ...
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... flexible and portable clinical molecular diagnostic system designed ... Care market.  At just 9 inches tall, and ... run the same high quality PCR-based Xpert® cartridges ... highly accurate clinical molecular diagnostic tests to be ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announce that it has received final approval for its common ... Stock Exchange (the "TSX"). The Company,s common shares will commence ... 2015 under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares ... About ESSA Pharma Inc. ESSA Pharma is ...
Breaking Medicine Technology:Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... (NASDAQ: MASI ) today announced that in line ... Cost of Care by Taking Noninvasive Monitoring to New Sites ... (SpHb®) will further the company,s stated mission,  Masimo is introducing ... ransfusion R elated C ost R eduction ...
... JAZZ ) today announced that the company will host ... 2011 at 4:30 p.m. EST/9:30 p.m. GMT. During the call, ... quarter and full year 2011 financial results. The ... Investors section of the Jazz Pharmaceuticals, website at www.jazzpharmaceuticals.com ...
Cached Medicine Technology:Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 2Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 3Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 4Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 5Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 6Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price 7
(Date:7/28/2015)... Boston, MA (PRWEB) , ... July 28, 2015 , ... ... developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but ... One thing individuals can do is to take part in a clinical trial, reports ...
(Date:7/28/2015)... ... July 28, 2015 , ... The ... Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation ... individuals with active yet undetected sub-clinical disease, who are at risk of experiencing ...
(Date:7/28/2015)... ... July 28, 2015 , ... For more than two ... based its selection process on the foundation of peer nominations. Physicians nominate other ... any area of medicine and in any part of the country. Physicians cannot ...
(Date:7/28/2015)... ... July 28, 2015 , ... One ... including Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression ... Designed by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include ...
(Date:7/28/2015)... ... , ... Nurses across all settings increasingly provide care to people with mental ... mental health services (SAMHSA, 2013) and the implementation of the Affordable Care Act is ... the largest workforces who provide care to persons with mental health disorders. Providing this ...
Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
... being circulated in South Asia for various ailments like malaria, ... a British doctor in Laotian capital, Vientiane, the drugs have ... find out. ,World Health Organization states that majority ... been treated with the original drug. They also add that ...
... the makers of ADHD drugs to indicate the contra indications ... cardiovascular risks. ,Dr. Steven Galson, director of the ... these drugs are immensely useful in treating patients with ADHD, ... He also said that FDA is working in tandem ...
... of your wedding celebration. The world-renowned research and care center ... save lives of cancer patients. Couples getting married are encouraged ... Jimmy Fund. Dana-Farber treats both children and adults, and is ... ,A package of 10 table cards, gift cards, or ...
... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
... Mukesh Haikerwal, today congratulated the Victorian Government on introducing ... child carers are trained in handling potentially deadly severe ... anaphylaxis program to be implemented nationally. ... to protect the children who suffer from severe allergies, ...
... who become impotent after prostate cancer surgery may find reprieve ... penis,// which assists in restoring the lost erectile function, according ... came to light after a study of nearly 44 patient ... function, following its loss after treatment for prostate cancer. ...
Cached Medicine News:Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:National Plan Needed for Severe Allergy Kids 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: